G01N 2333/7056
Selectin superfamily
Official title: Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
G01N2333/7056 (Selectin superfamily) appears on 68 US grants and 120 published applications in this corpus.
Search patents in G01N- Granted patents
- 68
- Published applications
- 120
- Assignees
- 87
- Inventors
- 284
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 14 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 4 |
| 2003 | 2 | 3 |
| 2004 | 0 | 5 |
| 2005 | 0 | 2 |
| 2006 | 1 | 5 |
| 2007 | 2 | 2 |
| 2008 | 4 | 3 |
| 2009 | 1 | 6 |
| 2010 | 2 | 7 |
| 2011 | 1 | 5 |
| 2012 | 1 | 2 |
| 2013 | 4 | 4 |
| 2014 | 0 | 4 |
| 2015 | 2 | 5 |
| 2016 | 1 | 7 |
| 2017 | 3 | 8 |
| 2018 | 1 | 7 |
| 2019 | 4 | 5 |
| 2020 | 3 | 2 |
| 2021 | 4 | 4 |
| 2022 | 3 | 9 |
| 2023 | 0 | 4 |
| 2024 | 2 | 4 |
| 2025 | 4 | 9 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels25 Aug 2026US 12,716,899 B2Biogen MA Inc.
- Immunochromatography16 Dec 2025US 12,498,304 B2FUJIFILM Corporation
- Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy14 Oct 2025US 12,442,820 B2Saitama Medical University
- Identification of platelet activating antibodies22 Jul 2025US 12,366,584 B2Retham Technologies, Inc.
- Immunological biomarker for predicting clinical effect of cancer13 May 2025US 12,298,311 B2Saitama Medical University
- Single-domain antibody specifically binding to cll1 protein and use thereof20 Aug 2026US 2026/0242486 A1Carbiogene Therapeutics Co., Ltd.
- Cd62l (l-selectin) aptamer and its application for t cell isolation6 Aug 2026US 2026/0227398 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- P-selectin mutants and modulation of integrin-mediated signaling21 May 2026US 2026/0139028 A1The Regents of the University of California
- Modified anti-galectin-9 antibody and uses thereof29 Jan 2026US 2026/0028407 A1FibroGen, Inc.
- Methods for detecting a cancer11 Dec 2025US 2025/0377360 A1Georgia Tech Research Corporation
Most cited
By later US patents
- Nucleic acid ligands of tissue target118US 6,127,119 ANeXstar Pharmaceuticals, Inc. · 2000
- Systematic evolution of ligands by exponential enrichment: tissue selex104US 5,712,375 ANeXstar Pharmaceuticals, Inc. · 1998
- Systematic evolution of ligands by exponential enrichment: tissue selex65US 5,789,157 ANeXstar Pharmaceuticals, Inc. · 1998
- Treatment for atherosclerosis and other cardiovascular and inflammatory diseases63US 5,380,747 AEmory University · 1995
- Nucleic acid ligands of tissue target58US 5,688,935 ANeXstar Pharmaceuticals, Inc. · 1997